5-(3-thienyl)[1,2,4]triazolo[1,5-a]pyridin-2-amine | 1124382-61-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 三唑并吡啶类
• 英文名称: 5-(3-thienyl)[1,2,4]triazolo[1,5-a]pyridin-2-amine
• 英文别名: 5-thiophen-3-yl-[1,2,4]triazolo[1,5-a]pyridin-2-amine
• CAS: 1124382-61-1
• 化学式: C₁₀H₈N₄S
• 分子量: 216.266
• InChiKey: GQFCOXGQMLCIPX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  84.4
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-(3-thienyl)[1,2,4]triazolo[1,5-a]pyridin-2-amine 、 氯化烟碱盐酸盐 生成 N-[5-(3-thienyl)[1,2,4]triazolo[1,5-a]pyridin-2-yl]nicotinamide
  参考文献：
  名称：

  TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS

  摘要：

  本发明涉及公式（I）的三唑吡啶化合物，其用作药物，用于治疗自身免疫性疾病、炎症性疾病、心血管疾病和/或神经退行性疾病以及其制备过程。

  公开号：

  US20120238565A1
• 作为产物：
  描述：

  ethyl ({[6-(3-thienyl)pyridin-2-yl]amino}carbonothioyl)carbamate 在 盐酸羟胺 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 乙醇 为溶剂， 反应 5.0h， 以82%的产率得到5-(3-thienyl)[1,2,4]triazolo[1,5-a]pyridin-2-amine
  参考文献：
  名称：

  [EN] TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS
  [FR] COMPOSÉS DE TRIAZOLOPYRIDINE ET LEUR UTILISATION COMME INHIBITEURS DE ASK

  摘要：

  本发明涉及三唑吡啶化合物，其化学式为（I），其用作药物，用于治疗自身免疫性疾病、炎症性疾病、心血管疾病和/或神经退行性疾病，以及其制备方法。

  公开号：

  WO2009027283A1

文献信息

• [EN] [1,2,4]TRIAZOLO[1,5-A]PYRIDINE AND [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE COMPOUNDS AND THEIR USE<br/>[FR] COMPOSÉS [1,2,4]TRIAZOLO[1,5-A]PYRIDINE ET [1,2,4]TRIAZOLO[1,5-C]PYRIMIDINE ET LEUR UTILISATION
  申请人：CANCER REC TECH LTD

  公开号：WO2009047514A1

  公开（公告）日：2009-04-16

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.

  本发明一般涉及治疗化合物领域，更具体地涉及某些三唑化合物（以下简称为TAZ化合物），特别是某些[1,2,4]三唑并[1,5-a]吡啶和[1,2,4]三唑并[1,5-c]嘧啶化合物，这些化合物等等，可以抑制AXL受体酪氨酸激酶功能。本发明还涉及包括这些化合物的药物组合物，以及使用这些化合物和组合物，无论是体外还是体内，来抑制AXL受体酪氨酸激酶功能，并用于治疗由AXL受体酪氨酸激酶介导的疾病和病况，通过抑制AXL受体酪氨酸激酶功能得到缓解的疾病和病况等，包括增生性疾病如癌症等。
• Triazolopyridine Compounds and Their Use as Ask Inhibitors
  申请人：Swinnen Dominique

  公开号：US20100197681A1

  公开（公告）日：2010-08-05

  The present invention relates to triazolopyridine compounds according to Formula (I), their use as medicament, for treating autoimmune disorders, inflammatory diseases, cardiovascular diseases and/or neurodegenerative diseases and a process for their preparation.

  本发明涉及按照公式（I）的三唑吡啶化合物，它们的用途是作为药物治疗自身免疫性疾病、炎症性疾病、心血管疾病和/或神经退行性疾病以及它们的制备方法。
• TRIAZOLE DERIVATIVES AS KINASE INHIBITORS
  申请人：Wilson Francis

  公开号：US20100227800A1

  公开（公告）日：2010-09-09

  The invention relates to compounds of formula (I); wherein X and R 1 to R 5 have the meaning as cited in the description and the claims. Said compounds are useful as protein kinase inhibitors, especially inhibitors of Itk or PI3K, for the treatment or prophylaxis of immunological, inflammatory or allergic disorders. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the production of and use as medicaments.

  本发明涉及式(I)的化合物；其中X和R1至R5的含义如所述及权利要求中所述。所述化合物可用作蛋白激酶抑制剂，特别是Itk或PI3K的抑制剂，用于治疗或预防免疫、炎症或过敏性疾病。本发明还涉及包括所述化合物的制药组合物，以及制备这些化合物的方法以及作为药物的生产和使用。
• TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE AS ASK INHIBITORS
  申请人：SWINNEN DOMINIQUE

  公开号：US20120238565A1

  公开（公告）日：2012-09-20

  The present invention relates to triazolopyridine compounds according to Formula (I), their use as medicament, for treating autoimmune disorders, inflammatory diseases, cardiovascular diseases and/or neurodegenerative diseases and a process for their preparation.

  本发明涉及公式（I）的三唑吡啶化合物，其用作药物，用于治疗自身免疫性疾病、炎症性疾病、心血管疾病和/或神经退行性疾病以及其制备过程。
• [1,2,4]Triazolo[1,5-a]Pyridine and [1,2,4]Triazolo[1,5-c]Pyrimidine Compounds and Their Use
  申请人：Cancer Research Technology Limited

  公开号：US20140155594A1

  公开（公告）日：2014-06-05

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain triazolo compounds (referred to herein as TAZ compounds), and especially certain [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine compounds, which, inter alia, inhibit AXL receptor tyrosine kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit AXL receptor tyrosine kinase function, and in the treatment of diseases and conditions that are mediated by AXL receptor tyrosine kinase, that are ameliorated by the inhibition of AXL receptor tyrosine kinase function, etc., including proliferative conditions such as cancer, etc.

  本发明涉及治疗化合物领域，更具体地涉及某些三唑化合物（在此称为TAZ化合物），特别是某些[1,2,4]三唑并[1,5-a]吡啶和[1,2,4]三唑并[1,5-c]嘧啶化合物，其中包括抑制AXL受体酪氨酸激酶功能的化合物。本发明还涉及包括这些化合物的制药组合物，以及使用这些化合物和组合物在体内外抑制AXL受体酪氨酸激酶功能，并用于治疗由AXL受体酪氨酸激酶介导的疾病和病症，通过抑制AXL受体酪氨酸激酶功能得到缓解的疾病和病症，包括增生性疾病如癌症等。